Price
Financials
Standalone, Rs crore| Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.02 | 0.09 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Profit | -0.02 | -0.09 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| OPM % | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.02 | -0.09 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tax % | 0.00% | 0.00% | 0.00% | |||||||||
| Net Profit | -0.02 | -0.09 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS in Rs | -0.01 | -0.04 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.00 | 0.00 | 0.01 | 0.26 | 0.09 | 0.41 | 0.10 | 0.00 | 0.00 |
| Operating Profit | 0.00 | 0.00 | -0.01 | -0.26 | -0.09 | -0.41 | -0.10 | 0.00 | 0.00 |
| OPM % | |||||||||
| Other Income | 0.03 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.03 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 46.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | -46.77 | 0.03 | -0.26 | -0.09 | -0.41 | -0.10 | 0.00 | 0.00 |
| Tax % | -1.35% | 33.33% | 0.00% | 0.00% | 0.00% | 0.00% | |||
| Net Profit | 0.00 | -46.14 | 0.02 | -0.26 | -0.09 | -0.41 | -0.10 | 0.00 | 0.00 |
| EPS in Rs | 0.00 | -22.71 | 0.01 | -0.13 | -0.04 | -0.20 | -0.05 | 0.00 | 0.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | % | ||
| Compounded Profit Growth | % | % | % | 100% | ||
| Stock Price CAGR | % | -4% | % | % | ||
| Return on Equity | % | % | % | % |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Sep 2021 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19.74 | 19.74 | 19.74 | 19.74 | 19.74 | 19.74 | 19.74 | 19.74 | 19.74 |
| Reserves | 16.22 | -29.92 | -29.90 | -30.16 | -30.24 | -30.65 | -30.75 | -30.76 | -30.76 |
| Borrowings | 10.98 | 11.18 | 10.39 | 10.66 | 10.75 | 11.14 | 11.22 | 11.18 | 11.18 |
| Other Liabilities | 1.39 | 0.00 | 0.02 | 0.01 | 0.00 | 0.02 | 0.00 | 0.03 | 0.02 |
| Total Liabilities | 48.33 | 1.00 | 0.25 | 0.25 | 0.25 | 0.25 | 0.21 | 0.19 | 0.18 |
| Fixed Assets | 19.12 | 0.16 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 |
| CWIP | 28.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.08 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
| Other Assets | 1.00 | 0.81 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.01 | 0.00 |
| Total Assets | 48.33 | 1.00 | 0.25 | 0.25 | 0.25 | 0.25 | 0.21 | 0.19 | 0.18 |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -0.22 | 0.03 | -0.26 | -0.09 | -0.39 | -0.08 | 0.00 | |
| Cash from Investing Activity | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash from Financing Activity | 0.21 | 0.02 | 0.26 | 0.09 | 0.39 | 0.08 | -0.03 | |
| Net Cash Flow | -0.01 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 | |
| Free Cash Flow | -0.22 | 0.01 | -0.26 | -0.09 | -0.39 | -0.08 | 0.00 | |
| CFO/OP | -400% | 100% | 100% | 95% | 80% |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||
| Inventory Days | ||||||||
| Days Payable | ||||||||
| Cash Conversion Cycle | ||||||||
| Working Capital Days | ||||||||
| ROCE % | -194.24% | 4.88% | -110.64% | -36.73% | -170.83% | -45.45% | 0.00% |
| Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 39.30% | 39.30% | 39.30% | 39.30% | 39.30% | 39.30% | 39.30% | 39.30% | 39.30% | 39.30% | 39.30% | 39.30% |
| Public | 60.70% | 60.70% | 60.70% | 60.70% | 60.70% | 60.70% | 60.70% | 60.70% | 60.70% | 60.70% | 60.70% | 60.70% |
| No. of Shareholders | 40,789 | 40,784 | 40,782 | 40,773 | 40,722 | 40,733 | 40,735 | 40,735 | 40,739 | 40,740 | 40,740 | 40,733 |
Fundamentals
Market Cap₹ 9.23 Cr.
Current Price₹ 4.54
Book Value₹ -5.42
ROCE0.00 %
ROE%
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)%
Compounded Profit Growth (TTM)100%
Standalone figures.
Valuation
P/B, 3-year average-2.19x
P/B, 5-year average-2.19x
Profitability
ROE3.83%
ROCE-170.83%
ROA-164.00%
ROE, 3-year average2.41%
ROCE, 3-year average-106.07%
ROA, 3-year average-101.33%
ROE, 5-year average-70.19%
ROCE, 5-year average-101.51%
ROA, 5-year average-97.57%
ROIC (approx.)-215.79%
Per share
EPS (TTM)Rs -0.20
EPS (latest year)Rs -0.20
EPS (latest quarter)Rs -0.00
EPS, 3-year averageRs -0.12
EPS, 5-year averageRs -4.61
Book value per shareRs -5.37
Cash flow per shareRs -0.19
Free cash flow per shareRs 0.00
Leverage
Total debtRs 11 Cr
Cash and bankRs 0 Cr
Net debtRs 11 Cr
Debt to equity-1.02x
Owners' fund to total sources-4364.00%
Debt to assets4456.00%
Cash flow
Cash from Operating Activity (latest year)Rs -0 Cr
Cash from Financing Activity (latest year)Rs 0 Cr
Free cash flow (latest year)Rs 0 Cr
FCFE (approx.: FCF + change in debt)Rs 0 Cr
Statement figures
Operating profit (latest quarter)Rs -0 Cr
EBITDA (TTM)Rs -0 Cr
PBDT (TTM)Rs -0 Cr
Profit before tax (TTM)Rs -0 Cr
Net profit (TTM)Rs -0 Cr
Net profit (latest year)Rs -0 Cr
Net profit (latest quarter)Rs -0 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total income (latest year)Rs 0 Cr
Share capitalRs 20 Cr
ReservesRs -31 Cr
Shareholders' fundsRs -11 Cr
Total assetsRs 0 Cr
Net blockRs 0 Cr
InvestmentsRs 0 Cr
Other liabilitiesRs 0 Cr
Shares outstanding (crore)2.03
Ownership
Promoter holding39.30% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 2 of 6| serious | Negative equity Shareholders' equity is negative |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Dec 2021Sales ₹0 Cr.
Net profit ₹0 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Mesco Pharmaceuticals Ltd?
Mesco Pharmaceuticals Ltd (MESCOPHARM) has a market capitalisation of Rs 9.23 Cr. at the close.
What were Mesco Pharmaceuticals Ltd's latest quarterly results?
In the Dec 2021 quarter, Mesco Pharmaceuticals Ltd sales was Rs 0 Cr and net profit was Rs 0 Cr.